Qizheng Tibetan Medicine Upgrades its Board of Directors’ Special Committees: Deep Integration of Strategic Investment and ESG to Drive Sustainable Development

Release time:

2025-11-30 13:52

On October 27, Qizheng Tibetan Medicine (002287.SZ) officially issued an announcement announcing the transformation of its “Board of Directors’ Strategic Investment Committee” into the “Board of Directors’ Strategic Investment and ESG Committee,” and simultaneously revised the committee’s detailed rules of operation. This move signifies that the company has fully integrated ESG (Environmental, Social, and Governance) principles into its core decision-making framework, marking an important practice in the Tibetan medicine industry toward standardizing ESG management.

Since 2024, the State Council has issued the "Several Opinions on Strengthening Regulation, Preventing Risks, and Promoting High-Quality Development of the Capital Market," and the Shanghai, Shenzhen, and Beijing stock exchanges have released the "Guidelines for Sustainability Reports of Listed Companies." China's domestic sustainability framework is accelerating its formation, and ESG has shifted from being a "voluntary action" for listed companies to becoming an "essential requirement" for high-quality development.

As a sector closely linked to people’s health and well-being, the ESG performance of pharmaceutical companies not only concerns compliance standards but also directly affects product quality, patient rights, and market capitalization recognition. Feng Ping, Senior Vice President and Board Secretary of Qizheng Tibetan Medicine, stated that this adjustment represents a crucial strategic move in response to regulatory requirements and the company’s current operational and developmental needs: On the one hand, by integrating ESG into the board-level decision-making process, we are ensuring effective alignment between ESG initiatives and strategic investments. On the other hand, by leveraging specialized committees, we are systematically enhancing the standardization and professionalism of ESG management, thereby strengthening our capacity for sustainable development.

Core Adjustment: Dual Upgrade of Name and Responsibilities

This adjustment focuses on two core aspects: “name optimization” and “expanded responsibilities,” while also ensuring the continuity of the committee’s operations. The specific details are as follows.

First, the name has been adjusted to clearly define the strategic positioning of ESG. The former “Board of Directors’ Strategic Investment Committee” has been officially renamed the “Board of Directors’ Strategic Investment and ESG Committee.” This renaming directly underscores the equal importance of ESG alongside strategy and investment, thereby breaking away from the previous “dependent” positioning of ESG efforts and making it an integral part of the Board’s core decision-making process. Second, the committee’s responsibilities have been expanded to establish five key ESG functions. Building on its original responsibilities, the committee has added five new specialized ESG duties: developing a top-level ESG framework; identifying the ESG impacts, risks, and opportunities associated with the company’s key matters; monitoring, inspecting, and evaluating the progress and completion of ESG-related objectives; setting up dedicated ESG initiatives; and reviewing ESG reports.

To avoid disrupting work continuity, this adjustment involves only changes to the committee’s name and responsibilities; the committee’s composition, members’ positions, and terms of office remain unchanged. This ensures that the original strategic investment decision-making process remains unaffected and ESG responsibilities can be swiftly implemented.

From Practical Benchmark to Governance Model

Leading Tibetan medicine company spearheads ESG upgrades in the industry.

This structural adjustment represents a “systemic leap” for Qizheng Tibetan Medicine, built upon years of outstanding ESG practices. It not only strengthens the company’s own foundation for sustainable development but also provides a replicable model—covering “top-level design, operational control, implementation, and iterative review”—for the Tibetan medicine and traditional Chinese medicine industries.

Publicly available information shows that in 2025, Qizheng Tibetan Medicine received a WindESGA-level rating, as did Huazheng Index—a recognition that stems from its sustained commitment to deepening efforts across the three key dimensions: environment, society, and governance. In recent years, the company has also successively earned accolades such as the ESG Competitiveness Model—Strategic Public Welfare Honor on the “2025 Golden Bee Corporate Social Responsibility·China List”; the Silver Award for “Corporate ESG Practice Innovation” at the 2023 ECIFESTIVAL; and honors including “CSRCHINA Annual Best Sustainable Development,” “Annual Best Responsible Corporate Brand,” and “2020 UN Sustainable Development Goals China Pioneer” at the 5th CSR China Education List in 2021. As of the end of 2024, the Qizheng Company’s Public Welfare Foundation had cumulatively invested 169.2 million yuan in public welfare initiatives. Moreover, the company has voluntarily disclosed sustainability reports for 16 consecutive years, setting an industry benchmark for ESG governance that combines “national characteristics” with “global perspectives.”